Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr-May:240:107990.
doi: 10.1016/j.rmed.2025.107990. Epub 2025 Feb 11.

A patient journey map for people living with autoimmune pulmonary alveolar proteinosis

Affiliations
Free article

A patient journey map for people living with autoimmune pulmonary alveolar proteinosis

Ali Ataya et al. Respir Med. 2025 Apr-May.
Free article

Abstract

Introduction: Patients with autoimmune pulmonary alveolar proteinosis (PAP) face a complicated journey (physically, emotionally, and financially) to receive the correct diagnosis and treatment. We developed a patient journey map (PJM) to describe the experiences and needs of patients with autoimmune PAP in the USA.

Methods: This PJM was developed in four stages: (1) analysis of existing literature; (2) patient advisory board meetings (n = 7); (3) an online survey (n = 19); and (4) a validation workshop (n = 6).

Results: Four phases of the patient journey were identified: (1) symptoms and experience before diagnosis; (2) diagnosis; (3) treatment; and (4) ongoing monitoring. Patients reported heterogeneous and indirect diagnostic pathways, often waiting months or years for the correct diagnosis. The majority reported at least one misdiagnosis, most commonly pneumonia. Treatment pathways varied substantially, and current treatments and off-label therapies were frequently described as burdensome, emotionally taxing, and/or financially worrisome. Patients described their journey as an "emotional rollercoaster," especially during pre-diagnosis and treatment. Patients reported common barriers to care, particularly insurance problems and access to expert care. Patients specifically cited the need for improved education on autoimmune PAP within the medical community and increased help with insurance challenges related to current treatments.

Conclusions: This PJM provides insights on patients' journeys with autoimmune PAP. Patients reported inconsistent, burdensome, and circuitous journeys. This PJM provides the medical community with valuable information on patients' needs and increases awareness of this rare disease. Over time, these factors may improve diagnosis, treatment, and the holistic experience of patients with autoimmune PAP.

Keywords: Autoimmune pulmonary alveolar proteinosis; GM-CSF; Interstitial lung disease; Patient experience map; Patient journey map; Pulmonary alveolar proteinosis; Whole lung lavage.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Niki Plomaritis reports financial support was provided by Savara Inc. Ali Ataya reports a relationship with Lungpacer Medical Inc that includes: consulting or advisory. Ali Ataya reports a relationship with Partner Therapeutics Inc that includes: consulting or advisory. Ali Ataya reports a relationship with Savara Inc that includes: consulting or advisory. Niki Plomaritis reports a relationship with Savara Inc that includes: consulting or advisory. Michele Rhee reports a relationship with Savara Inc that includes: employment and may hold equity or stocks. Brian Robinson reports a relationship with Savara Inc that includes: employment and may hold equity or stocks. Swaminathan Perinkulam Sathyanarayanan has no competing interests to declare.

References

Supplementary concepts